Free Trial

Ovid Therapeutics (OVID) Competitors

Ovid Therapeutics logo
$1.57 -0.08 (-4.85%)
Closing price 04:00 PM Eastern
Extended Trading
$1.57 +0.00 (+0.06%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OVID vs. OCGN, INBX, CMPX, FULC, RAPT, CYRX, GLUE, PRTC, SLDB, and ADCT

Should you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include Ocugen (OCGN), Inhibrx Biosciences (INBX), Compass Therapeutics (CMPX), Fulcrum Therapeutics (FULC), Rapt Therapeutics (RAPT), CryoPort (CYRX), Monte Rosa Therapeutics (GLUE), PureTech Health (PRTC), Solid Biosciences (SLDB), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry.

Ovid Therapeutics vs. Its Competitors

Ovid Therapeutics (NASDAQ:OVID) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Ovid Therapeutics has a net margin of -574.44% compared to Ocugen's net margin of -1,197.71%. Ovid Therapeutics' return on equity of -58.87% beat Ocugen's return on equity.

Company Net Margins Return on Equity Return on Assets
Ovid Therapeutics-574.44% -58.87% -43.18%
Ocugen -1,197.71%-255.25%-86.79%

In the previous week, Ovid Therapeutics had 1 more articles in the media than Ocugen. MarketBeat recorded 3 mentions for Ovid Therapeutics and 2 mentions for Ocugen. Ocugen's average media sentiment score of 0.91 beat Ovid Therapeutics' score of 0.50 indicating that Ocugen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ovid Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ocugen
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ovid Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 4.2, indicating that its stock price is 320% more volatile than the S&P 500.

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 13.1% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 4.4% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ovid Therapeutics has higher earnings, but lower revenue than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ovid Therapeutics$570K195.86-$26.43M-$0.53-2.96
Ocugen$4.05M116.20-$54.05M-$0.20-8.05

Ovid Therapeutics presently has a consensus target price of $3.70, suggesting a potential upside of 135.67%. Ocugen has a consensus target price of $7.00, suggesting a potential upside of 334.78%. Given Ocugen's higher probable upside, analysts plainly believe Ocugen is more favorable than Ovid Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ovid Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Ocugen
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Ovid Therapeutics beats Ocugen on 12 of the 17 factors compared between the two stocks.

Get Ovid Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OVID vs. The Competition

MetricOvid TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$117.33M$3.41B$6.10B$10.55B
Dividend YieldN/A2.29%5.73%4.78%
P/E Ratio-2.968.1163.4322.98
Price / Sales195.86486.03604.86133.16
Price / CashN/A46.9737.8662.13
Price / Book1.6410.5012.396.65
Net Income-$26.43M-$52.47M$3.32B$276.79M
7 Day Performance-9.77%-1.00%-0.24%-1.51%
1 Month Performance37.72%14.49%9.56%5.45%
1 Year Performance33.05%13.92%71.67%36.24%

Ovid Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OVID
Ovid Therapeutics
4.259 of 5 stars
$1.57
-4.8%
$3.70
+135.7%
+43.5%$117.33M$570K-2.9660
OCGN
Ocugen
1.5303 of 5 stars
$1.82
+2.8%
$6.00
+229.7%
+76.3%$517.38M$4.05M-9.1080
INBX
Inhibrx Biosciences
1.6158 of 5 stars
$34.96
-1.9%
N/A+128.3%$516.41M$200K-3.30166
CMPX
Compass Therapeutics
2.8097 of 5 stars
$3.67
-0.8%
$13.10
+256.9%
+149.7%$511.64M$850K-8.1620
FULC
Fulcrum Therapeutics
1.2778 of 5 stars
$9.50
+3.0%
$9.60
+1.1%
+163.4%$498.72M$80M-7.79100News Coverage
RAPT
Rapt Therapeutics
3.1705 of 5 stars
$29.87
-0.9%
$23.50
-21.3%
+86.7%$498.45M$1.53M-2.1180Analyst Forecast
Analyst Revision
CYRX
CryoPort
2.7799 of 5 stars
$9.98
+3.1%
$12.56
+25.8%
+35.5%$484.65M$228.38M7.501,186News Coverage
GLUE
Monte Rosa Therapeutics
2.9296 of 5 stars
$7.66
-1.0%
$15.33
+100.2%
+117.0%$478.02M$75.62M21.2890
PRTC
PureTech Health
0.2127 of 5 stars
$18.76
-1.7%
N/A-11.7%$461.13M$4.83M0.00100Short Interest ↑
Gap Down
SLDB
Solid Biosciences
2.8063 of 5 stars
$5.48
-7.1%
$15.00
+173.7%
-4.7%$459.43MN/A-1.96100
ADCT
ADC Therapeutics
2.4297 of 5 stars
$4.43
+8.6%
$7.75
+74.9%
+40.2%$459M$70.84M-2.82310News Coverage
Analyst Forecast
Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:OVID) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners